Mangoceuticals, INC S-1 registration statements

Mangoceuticals, Inc. reports significant net losses and declining revenues for recent periods, while pursuing strategic alternatives and facing substantial dilution from ongoing capital raises and related party transactions.

Mangoceuticals, Inc. filed an S-1 registration statement for the resale of up to 2,640,178 shares of common stock by selling stockholders, while reporting significant recurring net losses and a going concern doubt.

Mangoceuticals, Inc. has filed an S-1 registration statement to allow existing shareholders to resell up to 4,461,718 shares of common stock, while the company continues to report significant net losses and faces a lawsuit from Eli Lilly and Company.

Mangoceuticals registers shares for resale by selling stockholders, detailing its growth strategy focused on marketing, telemedicine, and subscription plans.

Mangoceuticals is registering shares for resale by selling stockholders, with proceeds to the company from ELOC and warrant exercises used for working capital.

Mangoceuticals is registering for the resale of over 30 million shares of common stock by selling stockholders, involving commitment shares, ELOC shares, warrant shares, and preferred conversion shares.